Apollomics Inc. Class A Ordinary Shares

APLM

...

APLM: Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.

Show APLM Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of APLM by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by APLM's directors and management

No recent Insider Trading for this ticker

Insider Trading Dashboard

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

Patent Title: Anti pd-1 antibodies Jan. 24, 2023
Patent Title: Anti pd-l1 antibodies Sep. 07, 2021
Patent Title: Anti pd-1 antibodies Apr. 20, 2021

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on APLM's company Twitter account

WallStreetBets

Number of mentions of APLM in WallStreetBets Daily Discussion

APLM News

Recent insights relating to APLM

CNBC Recommendations

Recent picks made for APLM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in APLM

Corporate Flights

Flights by private jets registered to APLM